Stockpolly
Search
CTNM · NASDAQ · Biotechnology

Contineum Therapeutics (CTNM)

Discovers and develops oral small-molecule therapies for neuroscience, inflammation and immunology.

$16.82
Pre-market−0.41 (−2.41%)
At close$17.24(+4.14%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
810101113−85181815171717
Research & development68881013141411131213
222334444455
General & administrative222334444455
Other expenses00000−102000000
Operating income−8−10−10−11−1385−18−18−15−17−17−17
22223−99222222
Interest income222233222232
Other non-operating income−2−2−2−2−399000000
Income before tax−6−8−8−9−10−15−16−16−13−15−14−15
Income tax expense000000000000
Net income from continuing operations−6−8−8−9−10−15−16−16−13−15−14−15
Net income−6−8−8−9−10−15−16−16−13−15−14−15
EPS, basic−$0.25−$0.05−$0.33−$0.35−$0.40−$0.56−$0.62−$0.62−$0.45−$0.49−$0.39−$0.40
EPS, diluted−$0.25−$0.05−$0.33−$0.35−$0.40−$0.56−$0.62−$0.62−$0.45−$0.49−$0.39−$0.40
Weighted average shares, basic252526262626262628313737
Weighted average shares, diluted252526262626262628313737
EBITDA−6−8−8−9−10−14−18−18−15−17−17−17
Depreciation & amortization000000000000
EBIT−6−8−8−9−10−15−18−18−15−17−17−17